Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors.
Jian MiaoPharmaceutical Sciences Program, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
David L WilliamsDepartment of Surgery, Quillen College of Medicine, East Tennessee State University, Johnson City, Tennessee, USA.
Michael D KruppaCenter of Excellence in Inflammation, Infectious Disease, and Immunity, East Tennessee State University, Johnson City, Tennessee, USA.
Brian M PetersDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID 0000-0002-0445-2077
Funding
Training Innate Immunity: A new approach to the treatment of SepsisR01GM119197 · NIGMS · EAST TENNESSEE STATE UNIVERSITY · PI SHERWOOD, EDWARD R, WILLIAMS, DAVID L. · 2016 to 2024
$4.6M
Innate Immunity and Cardiovascular Function in SepsisR01GM083016 · NIGMS · EAST TENNESSEE STATE UNIVERSITY · PI LI, CHUANFU, WILLIAMS, DAVID L. · 2009 to 2021
$3.8M
Candidalysin: a key mediator of Candida vaginitis immunopathologyR01AI134796 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Brian M Peters · 2018 to 2026
$2.9M
Genetic Characterization of phosphomannan biosynthesis in C. aurisR21AI159877 · NIAID · EAST TENNESSEE STATE UNIVERSITY · PI KRUPPA, MICHAEL D · 2021 to 2022
$407k
HHS | National Institutes of Health (NIH) C0RR036551NIAID NIH HHS R01 AI134796NIAID NIH HHS R21 AI159877NIGMS NIH HHS R01 GM083016NIGMS NIH HHS R01 GM119197
6 · The paper itself
Abstract
To adapt to various host microenvironments, the human fungal pathogen
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Glycogen synthase activity in · full record | OpenQuestion